ASP Isotopes Inc.

ASP Isotopes operates through subsidiaries in the United Kingdom, South Africa, Iceland, the Cayman Islands, and Guernsey, with the UK entity owning the core technology. The company’s commercial activity is split across multiple geographies: specialist isotope development is managed through its international subsidiary structure, PET dose revenue is recognized in South Africa, and construction services were added in Hong Kong after the Skyline acquisition. The nuclear fuels business is also organized through UK and South African subsidiaries, reflecting the company’s intention to build production and commercialization capabilities in jurisdictions relevant to nuclear and industrial supply chains. Geography matters because the business depends on local regulatory approvals, specialized manufacturing and production sites, and cross-border supply chain execution.

ASP Isotopes faces substantial execution risk because most of its core isotope businesses are still in development and have not yet produced meaningful commercial revenue. The company’s ability to reach profitability depends on successful scale-up, regulatory approvals, and commercialization of enriched isotopes and nuclear fuel products, all of which are technically complex and capital intensive. Its business is also exposed to fair value volatility from convertible notes and other financing instruments, reflecting a funding model that has relied on equity and debt issuance rather than operating cash flow. In addition, the new construction segment introduces project execution, subcontracting, and margin risks, while the company’s cross-border footprint exposes it to trade policy, inflation, foreign exchange, and jurisdiction-specific regulatory risk.